ACLS Tachycardia Management Quiz

Hypovolemia is a common cause of stable narrow-complex tachycardia.

Polymorphic ventricular tachycardia is not treated with synchronized cardioversion in ACLS.

Synchronized cardioversion is not a recommended intervention for stable narrow-complex tachycardia in ACLS.

Dobutamine is not commonly used in ACLS for pulseless VT or VF.

The primary goal of ACLS during resuscitation efforts is to restore and maintain spontaneous circulation.

Assess for signs of instability before proceeding with further interventions.

The recommended initial dose of adenosine for regular narrow-complex tachycardia is 3 mg.

The recommended maximum dose of adenosine for stable SVT is 12 mg.

The recommended dose of epinephrine for pulseless ventricular tachycardia is 1 mg IV/IO every 3-5 minutes.

Capnography is the preferred method for confirming endotracheal tube placement during resuscitation.

The recommended initial energy level for synchronized cardioversion in hemodynamically unstable tachycardia is 100 joules.

Amiodarone is typically used in ACLS for pharmacological cardioversion of stable monomorphic ventricular tachycardia.

Synchronized cardioversion is the first-line therapy for unstable narrow-complex tachycardia in ACLS.

The recommended initial dose of amiodarone for pulseless VT or VF is 300 mg IV bolus over 10 minutes.

The maximum dose of lidocaine for stable ventricular tachycardia is 1.5 mg/kg.